New Zealand markets closed

Intercept Pharmaceuticals, Inc. (ICPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
15.240.00 (0.00%)
At close: 04:00PM EDT
15.24 0.00 (0.00%)
After hours: 06:53PM EDT

Intercept Pharmaceuticals, Inc.

10 Hudson Yards
37th Floor
New York, NY 10001
United States
646 747 1000
https://www.interceptpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees437

Key executives

NameTitlePayExercisedYear born
Mr. Jerome B. DursoPres, CEO & Director1.16MN/A1968
Mr. Andrew SaikChief Financial Officer485.07kN/A1969
Mr. Rocco VeneziaChief Accounting Officer & Treasurer660.62kN/A1976
Mr. Jared M. Freedberg J.D.Gen. Counsel691.46kN/A1968
Dr. M. Michelle Berrey M.D., M.P.H., MPH.Pres of R&D and Chief Medical Officer732.13kN/A1967
Mr. Nareg SagherianExec. Director of Global Investor RelationsN/AN/AN/A
Mr. David FordChief HR OfficerN/AN/A1970
Dr. Mark Pruzanski M.D.Founder, Advisor & DirectorN/AN/A1968
Ms. Linda M. RichardsonExec. VP & Chief Commercial OfficerN/AN/A1964
Paul NitschmannSr. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.

Corporate governance

Intercept Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 September 2022 is 5. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 6; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.